Pfizer stock gets a USD 0.43 dividend for December on NYSE

Published on 10/06/2026 at 16:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pfizer raised its 2026 revenue guidance midpoint by USD 500 million after second-quarter growth. Pfizer stock was trading at USD 27.26 on October 6, 2026.

Bauhaus-Poster mit geometrischen Formen und Schriftzug PHARMA, Symbolbild für Pfizer Inc — Geometrisches Bauhaus-Poster mit dem Wort PHARMA visualisiert die Branche von Pfizer Inc., ISIN US7170811035, künstlerisch, Illustration mit AI erstellt.

Pfizer Inc. (ISIN US7170811035) declared a USD 0.43 fourth-quarter dividend on October 6, 2026, with payment scheduled for December 7. The stock was trading at USD 27.26 on the NYSE at 10:40 a.m. ET, down 0.55 percent from the previous close.

Dividend decision sets the tone

According to Business Wire on October 6, 2026, the board approved the fourth-quarter cash dividend for shareholders of record at the close of business on November 6.

The payment will be Pfizer's 352nd consecutive quarterly dividend, according to the same company release. The decision gives the current stock story a direct income component while the company works through weaker COVID-related demand and patent-related pressure.

Revenue guidance rises by USD 500 million

Pfizer's second-quarter 2026 revenue was USD 15.034 billion, while GAAP net income attributable to common shareholders was negative USD 248 million and diluted GAAP EPS was negative USD 0.04 for the period.

In the Q2 2026 earnings call, Yahoo Finance reported that adjusted diluted EPS reached USD 0.77 and that management lifted the midpoint of full-year 2026 revenue guidance by USD 500 million, to USD 60.5 billion-USD 62.5 billion. Adjusted diluted EPS guidance remained USD 2.80-USD 3.00.

The comparison matters because the revenue range rose from USD 59.5 billion-USD 60.5 billion even as Pfizer reduced its expected 2026 COVID revenue to USD 4 billion from USD 5 billion. Non-COVID products therefore carry more of the recovery burden.

Analyst target sits above the stock

MarketBeat lists a Hold consensus from 21 analysts: 1 Strong Buy, 4 Buys, 14 Holds and 2 Sells. Its average price target is USD 28.39, which lies 4.1 percent above the USD 27.26 reference price.

That consensus leaves the dividend and the guidance increase competing with execution risks. MarketBeat also cites Pfizer's USD 2.80-USD 3.00 full-year adjusted EPS guidance, keeping the payout decision tied to the company's ability to convert its pipeline and non-COVID portfolio into durable earnings.

Pfizer stock remains below its yearly high

At USD 27.26 on October 6, 2026, Pfizer stock was USD 1.95 below its 52-week high of USD 29.21 and USD 3.64 above its 52-week low of USD 23.62. The market capitalization stood at USD 155.4 billion, with volume at 4,129,185 shares.